SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer

Carcinogenesis
Hailin TangXiaoming Xie

Abstract

The molecular mechanisms underlying triple-negative breast cancer (TNBC) pathology are not fully understood. Here, we reviewed the SOX8 transcript level in 24 types of cancer and normal tissues and the SOX8 expression pattern in breast cancer from the TCGA and METABRIC data sets and found that SOX8 was highly expressed in TNBC. We investigated the effect of SOX8 on tumorigenicity, migration and apoptosis in TNBC cell lines and xenografts models. We identified SOX8 as a functional oncogene that involved in the maintenance of stem-like capacities in TNBC cells. Through a promoter truncation experiment and ChIP experiment, we verified zinc finger E-box binding homeobox 1 (ZEB1) as a transcriptional activator of SOX8 that enhanced SOX8 expression by binding to its promoter. We evaluated the ZEB1 and the SOX8 levels in 240 TNBC patients and high expression of ZEB1 and SOX8 were significantly associated with poor prognosis. We demonstrated the significance of the ZEB1-SOX8 axis in regulating TNBC cancer stem-like cells (CSCs) and its connection with poor prognosis. Due to its vital role in TNBC CSCs, the ZEB1-SOX8 regulatory axis could be a promising therapeutic target for TNBC.

References

Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Jun 9, 2006·Nature·David W McCauley, Marianne Bronner-Fraser
Jun 19, 2008·Breast Cancer Research : BCR·Gabriella HonethCecilia Hegardt
Sep 30, 2010·Nature Reviews. Clinical Oncology·Lisa CareyLuca Gianni
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jan 18, 2011·Trends in Molecular Medicine·James PritchettKaren Piper Hanley
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Otto Metzger-FilhoMartine Piccart-Gebhart
Mar 20, 2014·Medical Oncology·Siquan ZhangXianfeng Ding
Jun 23, 2015·Cell Stem Cell·Jean-Christophe LarsimontCédric Blanpain
Sep 5, 2015·Cell Stem Cell·Michael D BrooksMax S Wicha
Nov 6, 2015·Trends in Pharmacological Sciences·Murugan KalimuthoKum Kum Khanna
Feb 16, 2016·Nature Communications·Waltraut LehmannThomas Brabletz
Feb 26, 2016·The British Journal of Dermatology·S R QuistH P Gollnick
Oct 19, 2016·Nature Reviews. Clinical Oncology·Giampaolo BianchiniLuca Gianni
Aug 1, 2016·Seminars in Cell & Developmental Biology·Ya-Ru Xu, Wan-Xi Yang
Oct 7, 2017·Nature Medicine·Eduard Batlle, Hans Clevers

❮ Previous
Next ❯

Citations

May 27, 2020·Journal of Cellular Physiology·Chao TuZhihong Li
Nov 17, 2020·Cancer Biology & Therapy·Wenyan TianYingmei Wang
Oct 17, 2020·Cancer Management and Research·Liangliang DongPing Sun
Dec 8, 2020·Therapeutic Advances in Medical Oncology·Bo ChenHailin Tang
Jan 20, 2020·Molecular Therapy. Nucleic Acids·Peng LiuXiaoming Xie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.